Scinai Immunotherapeutics Holds Annual Shareholder Meeting

Ticker: SCNI · Form: 6-K · Filed: Dec 23, 2025 · CIK: 1611747

Scinai Immunotherapeutics Ltd. 6-K Filing Summary
FieldDetail
CompanyScinai Immunotherapeutics Ltd. (SCNI)
Form Type6-K
Filed DateDec 23, 2025
Risk Levellow
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-actions, company-name-change

TL;DR

Scinai Immunotherapeutics held its shareholder meeting on 12/22/25 with over 13.8B shares voting.

AI Summary

On December 22, 2025, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 13,872,899,584. The company previously operated under the name BiondVax Pharmaceuticals Ltd. before changing its name on June 24, 2014.

Why It Matters

This filing confirms the company's operational status and shareholder engagement, which is crucial for investor confidence and future strategic decisions.

Risk Assessment

Risk Level: low — This is a routine administrative filing confirming a shareholder meeting, with no new financial or operational risks disclosed.

Key Numbers

  • 13,872,899,584 — Ordinary Shares (Total shares entitled to vote at the Annual Meeting of Shareholders.)

Key Players & Entities

  • Scinai Immunotherapeutics Ltd. (company) — Registrant
  • BiondVax Pharmaceuticals Ltd. (company) — Former company name
  • 13,872,899,584 (dollar_amount) — Ordinary shares entitled to vote
  • December 22, 2025 (date) — Annual Meeting of Shareholders date
  • June 24, 2014 (date) — Date of name change from BiondVax Pharmaceuticals Ltd.

FAQ

What was the date of Scinai Immunotherapeutics Ltd.'s Annual Meeting of Shareholders?

The Annual Meeting of Shareholders was held on December 22, 2025.

How many ordinary shares were entitled to vote at the meeting?

There were 13,872,899,584 Ordinary Shares entitled to vote.

What was Scinai Immunotherapeutics Ltd.'s former name?

The company's former name was BiondVax Pharmaceuticals Ltd.

When did Scinai Immunotherapeutics Ltd. change its name?

The date of the name change was June 24, 2014.

Is Scinai Immunotherapeutics Ltd. required to file annual reports under Form 20-F or Form 40-F?

The registrant indicates it files annual reports under Form 20-F.

Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-12-23 16:01:20

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scinai Immunotherapeutics Ltd December 23, 2025 /s/ Amir Reichman Amir Reichman Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.